Cabaletta Bio 株価情報 (NASDAQ: CABA)

Cabaletta Bio (NASDAQ:CABA) 株価情報

Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Cabaletta Bio Inc

Cabana Target Beta ETF

Cabana Target Drawdown 10 ETF

Cabana Target Leading Sector Moderate ETF

Combining 5G Connectivity, Advanced Thermal Imaging, a Slim Design, and Built-to-Endure Toughness

News

SONM

Sonim XP Pro Thermal 5G Debuts With Military-Grade Durability And Real-Time Thermal Data Streaming

Skanska Selects DXC Technology To Overhaul IT Infrastructure, Boost Efficiency, And Strengthen Security

Teledyne e2v Introduces Lince5M NIR, A High-Speed 5.2MP Sensor For Advanced Industrial And Medical Imaging

"Our Bengaluru expansion represents a critical step in our continued commitment to scaling our global operations and enhancing support for customers worldwide," said Therese Tucker, Founder and co-CEO at BlackLine. "India's deep talent pool and thriving technology ecosystem make it an ideal location to drive innovation, expand our capabilities, and accelerate our global impact to meet growing customer demand."

BlackLine Expands Bengaluru Operations With A 50,000-Square-Foot Office To Drive Global Innovation And Growth

<ul>
<li>New agreement spans packet core, signaling, charging &amp; policy solutions</li>
</ul>

ERIC

Bharti Airtel Partners With Ericsson To Deploy Advanced 5G Core Technology For India's 5G Evolution

51Talk Integrates AI Across Its Platform, Enhancing Personalized Learning And Operational Efficiency

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon has voiced criticism over the efficiency of the U.S. government and shown support for the Department of Government Efficiency (DOGE) overseen by Elon Musk.
What Happened: In an interview with <a href="https://www.cnbc.com/2025/02/24/jamie-dimon-us-government-inefficient-touts-elon-musk-doge-effort.html">CNBC</a>&#8216;s Leslie Picker on Monday, Dimon labeled the government as &#8220;inefficient&#8221; and &#8220;not very competent,&#8221; implying that it &#8220;needs a lot of work.&#8221; Although he didn&#8217;t provide a clear-cut response about his stance on DOGE&#8217;s initiatives, his remarks suggested a general endorsement.
Dimon also mentioned the Trump administration&#8217;s initiatives to cut spending and closely examine federal agencies, stating such actions &#8220;need to be done.&#8221; He underscored the need for building appropriate policies and procedures and questioned the benefits derived from government spending.
While Dimon expressed support for DOGE&#8217;s cost-cutting initiatives, he also cautioned against any potential overreach or illegal activities, stating that &#8220;the courts will stop it.&#8221; Nevertheless, Dimon added, "I'm hoping it's quite successful.&#8221;
SEE ALSO: <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43930754/bitcoin-ethereum-dogecoin-bleed-amid-trumps-tariff-threat-bybit-mega-breach-analyst-says-mid-bull-reset-not-unprecedented-full-blown-bear-market-not-yet-here">Bitcoin, Ethereum, Dogecoin Bleed Amid Trump&#8217;s Tariff Threat, Bybit Mega Breach: Analyst Says &#8216;Mid-Bull Reset&#8217; Not Unprecedented, Full-Blown Bear Market Not Yet Here</a>
Why It Matters: Dimon&#8217;s comments come in the backdrop of his recent reconciliation with Elon Musk, CEO of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>). In late January, Dimon referred to <a href="https://www.benzinga.com/startups/25/01/43339032/jamie-dimon-calls-elon-musk-our-einstein-after-years-of-feuds-weve-hugged-it-out-and-settled-differences-at-tech-summit">Musk as &#8216;Our Einstein&#8217;</a> after years of public feuds and legal disputes. The two reportedly &#8220;hugged it out&#8221; and settled their differences at a tech summit.
The JPMorgan CEO has also expressed his support for President Donald Trump&#8216;s tariff policy, previously. In January, he had told CNBC, that the upcoming tariffs by the Trump administration could be seen in a positive light. "If it's a little inflationary but it's good for national security, so be it. I mean, get over it," Dimon had said. 
Jamie Dimon recently courted controversy after he <a href="https://www.benzinga.com/markets/equities/25/02/43757032/jamie-dimon-goes-off-on-return-to-office-critics-you-dont-have-to-work-at-jpmorgan">condemned remote work</a>, arguing that it hinders creativity and negatively impacts the social and professional development of younger employees. 
Notably, while the JPMorgan CEO has voiced his support for Musk&#8217;s DOGE initiative, several others have criticized the transparency and working of DOGE. A <a href="https://www.benzinga.com/markets/25/02/43906977/elon-musks-doge-savings-of-55-billion-may-be-overstated-wsj-analysis-reveals-the-likely-actual-figure">recent analysis by WSJ</a> also revealed that the savings mentioned on the DOGE website could be overstated. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/personal-finance/25/02/43929806/dave-ramsey-says-its-very-difficult-to-trust-someone-in-pajamas-on-a-zoom-call-admits-hes-the-crotchety-old-boss">Dave Ramsey Says &#8216;It&#8217;s Very Difficult To Trust Someone In Pajamas On A Zoom Call&#8217;—Admits He&#8217;s &#8216;The Crotchety Old Boss&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

TSLA

Jamie Dimon Slams 'Inefficient' US Government, Backs Elon Musk's DOGE Initiative

EpoVIVE&#x2122;, an epoxy product portfolio offering a range of sustainable characteristics across multiple products, which will support customer sustainability initiatives. The EpoVIVE&#x2122; portfolio of Epoxy phenolic, resins and curing agents, represents a significant step forward in the commitment to drive sustainable innovation and foster value-chain collaboration. EpoVIVE&#x2122; products are developed with an environmentally conscious mindset.

Westlake Epoxy Introduces EpoVIVE At JEC World 2025, Advancing Sustainable Epoxy Solutions

<ul>
<li>Contentserv provides the all-in-one cloud-based platform for PIM, DAM, Content Syndication and Digital Shelf Analytics (DSA)</li>
<li>Platform enables FMCG companies to craft and optimize product content to reduce time to market, increase product sell-through and curate personalized consumer experiences</li>
</ul>

DASTY

Dassault Systemes' Centric Software Acquires AI-Powered PXM Leader Contentserv For €220M

Macro Economic Events

Econ #s

Economics

Germany Gross Domestic Product (YoY) For Q4 -0.2% Vs. -0.2% Est.; -0.3% Prior

Germany Gross Domestic Product (QoQ) For Q4 -0.2% Vs. -0.2% Est.; 0.1% Prior

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma&nbsp;
<ul>
<li>Approval offers access to new treatment options for newly diagnosed MM patients</li>
<li>Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with VRd significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma</li>
</ul>

Sanofi Gains Japanese Approval For Sarclisa In Newly Diagnosed Multiple Myeloma Patients

Billionaire entrepreneur and Dallas Mavericks owner Mark Cuban has called the U.S. healthcare system, &#8220;f&#x2A;&#x2A;&#x2A;&#x2A;d up&#8221; while highlighting deductibles as &#8220;the biggest problem in healthcare,&#8221; which are designed by insurance companies.
What Happened: Cuban explained in his latest X post that insurance companies design plans with higher deductibles and lower premiums leaving the work of bill collection in the hands of doctors and hospitals.
A deductible is the amount of money paid by the patient before their insurance company pays for the covered expenses as chosen under their policy.
&#8220;Often we choose higher deductibles because we are healthy or because we can only afford the lowest premium plan,&#8221; adds Cuban, inferring that if higher deductibles were left unpaid hospitals end up becoming &#8220;bill collectors,&#8221; &#8220;DESPITE HAVING NO SAY in the (insurance) plans&#8221; and deductibles bracket that patients choose.
"That is one fucked up system that needs to be redesigned," adds Cuban.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Want to know one of the biggest problems in healthcare? Deductibles. Deductibles are defined by the plans the insurance companies design. Then they are approved to be offered by the feds or employers. Then we the people decide what deductible we want when we choose our plans.…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1894236347847618571?ref_src=twsrc%5Etfw">February 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/government/regulations/25/02/43912631/apple-forced-to-kiss-the-ring-expert-questions-whether-trump-pushed-the-iphone-maker-for-500-billion-investment">Apple &#8216;Forced To Kiss The Ring&#8217;? Expert Questions Whether Trump Pushed The iPhone Maker For $500 Billion Investment</a>
Why It Matters: Cuban&#8217;s tweets shed light on the growing problem of high deductibles in the U.S. healthcare system.
The "higher deductibles" turn out to be out-of-pocket costs which create a barrier to accessing care, potentially leading to delayed treatment, worsening health conditions, and mounting medical debt.
Cuban concluded his post by calling out insurance company practices that contribute to healthcare costs, including &#8220;delay tactics&#8221; and denials of claims. He called for a redesigned system for patient well-being and fairness for healthcare providers.
Here is a list of Insurance sector ETFs that investors could look at:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>SPDR S&amp;P Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIE#NYSE">KIE</a>)</td>
<td>3.30%</td>
<td>17.59%</td>
</tr>
<tr>
<td>iShares US Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAK#NYSE">IAK</a>)</td>
<td>3.66%</td>
<td>17.32%</td>
</tr>
<tr>
<td>Invesco KBW Property &amp; Casualty Insurance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWP#NASDAQ">KBWP</a>)</td>
<td>-0.33%</td>
<td>12.48%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Monday. SPY declined 0.46% to $597.21, and QQQ plunged 1.18% to $519.87, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43906366/warren-buffetts-berkshire-boosts-bets-on-five-japanese-companies-admiration-has-consistently-grown-says-oracle-of-omaha-in-letter-to-shareholders">Warren Buffett&#8217;s Berkshire Boosts Bets On 5 Japanese Companies: Oracle Of Omaha Says Admiration &#8216;Has Consistently Grown&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Sector ETFs

Insurance

ETFs

iShares Dow Jones US Insurance Index Fund

KBWP

Mark Cuban Calls Deductibles 'The Biggest Problem' in Healthcare: 'System…Needs To Be Redesigned'

Will significantly shorten digital transformation development period

MIELY

Reported Earlier, Mitsubishi Electric Develops First-Ever System To Digitize Operator Expertise For Smarter Operations

TRGP

Reported Earlier, Targa Resources Prices $2B In Senior Notes: $1B 5.550% Due 2035 And $1B 6.125% Due 2055

Reported Earlier, Accenture Unveils AI Solutions To Help Businesses Leverage Google Cloud And Salesforce Technology

OXBR

Reported Earlier, Oxbridge Announces $3M Capital Raise Through Registered Offering And Private Placement

Unity also granted the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $90.0 million aggregate principal amount of Notes. The sale of the Notes to the initial purchasers is expected to close on February 27, 2025, subject to customary closing conditions.
The Notes will be general unsecured obligations of Unity and will not bear regular interest, and the principal amount of the Notes will not accrete. The Notes will mature on March 15, 2030, unless earlier converted, redeemed or repurchased.

Reported Earlier, Unity Prices Upsized $600M 0% Convertible Senior Notes Due 2030

Reported Earlier, EHang Forms Strategic Partnership With JAC Motors And Guoxian Holdings To Develop eVTOL Manufacturing Hub

Grupo Aeroportuario del (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAC#NYSE">PAC</a>) reported quarterly earnings of Ps. 4.50 per share which beat the analyst consensus estimate of Ps. 4.35 by 3.47 percent. This is a 16.23 percent increase over earnings of Ps .3.87 per share from the same period last year. The company reported quarterly sales of Ps .9.63 billion which beat the analyst consensus estimate of Ps. 9.02 billion by 6.67 percent. This is a 5.43 percent increase over sales of Ps. 9.13 billion the same period last year.

Earnings

Earnings Beats

Grupo Aeroportuario del Q4 2024 GAAP EPS Ps. 4.50 Beats Ps .4.35 Estimate, Sales Ps .9.63B Beat Ps. 9.02B Estimate

Press Releases

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

General

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Health Care

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Comments

Cabaletta Bio

ニュース

パートナーシップ

ベンジンガ・グローバル